Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years. These new classes of reagents target malignant plasma cells (PCs) and further modulate the immune microenvironment, which pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Yu-Tzu, Cho, Shih-Feng, Anderson, Kenneth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095980/
https://www.ncbi.nlm.nih.gov/pubmed/30147691
http://dx.doi.org/10.3389/fimmu.2018.01822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095980/
https://www.ncbi.nlm.nih.gov/pubmed/30147691
http://dx.doi.org/10.3389/fimmu.2018.01822

Ejemplares similares